ReviewCells2022
Bile Acids: Key Players in Inflammatory Bowel Diseases?
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 45 citations in OpenAlex.
- Microbiota-gut-brain axis and bile acids-driven neuromodulation.Neural regeneration research · 2026Article
- Application of Chinese Medicine in Treatment of Ulcerative Colitis and Elucidation of Relevant Mechanisms.Chinese journal of integrative medicine · 2026Review
- Bile Acid Dysregulation in Parkinson's Disease: Longitudinal Changes and Altered Metabolic Interactions.Biomolecules · 2026Article
- A Review on the Molecular Dynamics of EnterotypeInternational journal of molecular sciences · 2026Review
- The role of bile acid dynamics in inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease.Liver research (Beijing, China) · 2026Review
- Microbiome-Metabolome Axis in BALF Reveals Novel Diagnostic Biomarkers for Congenital Heart Disease-Associated Pulmonary Arterial Hypertension.Journal of cardiovascular development and disease · 2026Article
- Advances in research on the effects of bile acids and their receptors on intestinal function.Frontiers in nutrition · 2026Review
- Gut microbiota contributes to gestational diabetes mellitus by interfering with bile acid metabolism and resistin.Frontiers in cellular and infection microbiology · 2026Article
- Gegen Qinlian decoction alleviates ulcerative colitis by remodeling the gut microbiota-bile acid axis and inhibiting NLRP3-mediated pyroptosis.Frontiers in immunology · 2026Article
- Luohuazizhu Granules Alleviate Symptoms of Ulcerative ColitisCombinatorial chemistry & high throughput screening · 2026Article
- SGLT2 Inhibitors Confer Cardiovascular Protection via the Gut-Kidney-Heart Axis: Mechanisms and Translational Perspectives.Journal of cardiovascular development and disease · 2025Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Impact of Diquat on the Intestinal Health and the Composition and Function of the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2025Review
- The gut microbiome and cancer: from tumorigenesis to therapy.Nature metabolism · 2025Review
- An overview of basic pathophysiological interactions between gut bacteria and their host.Frontiers in nutrition · 2025Review
- New Baitouweng Decoction alleviated DSS-induced colitis through the FXR/NLRP3 signaling pathway by regulating gut microbiota and bile acids.Gastroenterology report · 2025Article
- Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Industrial diet intervention modulates the interplay between gut microbiota and host in semi-stray dogs.Animal microbiome · 2024Article
- Updating the Classification of Chronic Inflammatory Enteropathies in Dogs.Animals : an open access journal from MDPI · 2024Review
- Gut microbiota in cancer: insights on microbial metabolites and therapeutic strategies.Medical oncology (Northwood, London, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Inflammatory bowel diseases (IBDs) have emerged as a public health problem worldwide with a limited number of efficient therapeutic options despite advances in medical therapy. Although changes in the gut microbiota composition are recognized as key drivers of dysregulated intestinal immunity, alterations in bile acids (BAs) have been shown to influence gut homeostasis and contribute to the pathogenesis of the disease. In this review, we explore the interactions involving BAs and gut microbiota in IBDs, and discuss how the gut microbiota-BA-host axis may influence digestive inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.